- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00274716
Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MK0736 and MK0916 in Hypertensive Patients
The objective of this study is to evaluate the safety and efficacy of two investigational drugs (MK-0736 and MK-0916) in lowering blood pressure and body weight in patients with hypertension (high blood pressure).
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
Przegląd badań
Szczegółowy opis
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Hypertension systolic blood pressure (SBP) </= 160mm Hg and diastolic blood pressure (DBP): 90-105mm Hg
Exclusion Criteria:
- Pre-menopausal women
- patients currently taking more than two (2) blood pressure lowering medications
- Body Mas Index (BMI)>40 kg/m2 (morbidly obese patients)
- History of Alcohol abuse (<3 Years)
- History of diabetes,chronic kidney disease, Active liver disease, recent heart attack or stroke
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: High BMI:MK-0736 2mg→Placebo
Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
|
|
Eksperymentalny: High BMI:MK-0736 7mg→Placebo
Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
|
|
Eksperymentalny: High BMI:MK-0916 6mg→MK-0916 6mg
Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
|
|
Komparator placebo: High BMI:Placebo→Placebo
Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
|
|
Eksperymentalny: Low BMI:MK-0916 6mg→MK-0916 6mg
Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
|
|
Komparator placebo: Low BMI:Placebo→Placebo
Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 in Participants With Higher Body Mass Indices (BMI)
Ramy czasowe: Baseline and Week 12 (end of Phase A)
|
Sitting diastolic blood pressure measured in triplicate at baseline and after 12 weeks of study drug administration.
Mean value of the 3 measurements at the 2 timepoints was recorded.
|
Baseline and Week 12 (end of Phase A)
|
Number of Participants Who Reported a Clinical Adverse Event
Ramy czasowe: 24 weeks
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE.
A clinical AE was an AE reported as a result of a clinical examination.
|
24 weeks
|
Number of Participants Who Reported a Laboratory Adverse Event
Ramy czasowe: 24 weeks
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE.
A laboratory AE was an AE reported as a result of a laboratory assessment or test.
|
24 weeks
|
Number of Participants Who Were Discontinued From Study Due to Clinical Adverse Event
Ramy czasowe: 24 weeks
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE.
A clinical AE was an AE reported as a result of a clinical examination.
|
24 weeks
|
Number of Participants Who Were Discontinued From Study Due to Laboratory Adverse Event
Ramy czasowe: 24 weeks
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE.
A laboratory AE was an AE reported as a result of a laboratory assessment or test.
|
24 weeks
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12 in Participants With Higher Body Mass Indices (BMI)
Ramy czasowe: Baseline and Week 12 (end of Phase A)
|
Sitting systolic blood pressure measured in triplicate at baseline and after 12 weeks of study drug administration.
Mean trough value of the 3 measurements at the 2 timepoints was recorded.
|
Baseline and Week 12 (end of Phase A)
|
Change From Baseline in Body Weight (kg) at Week 12 in Participants With Higher BMI
Ramy czasowe: Baseline and Week 12 (end of Phase A)
|
Weight was measured in duplicate (2 measurements) at baseline and after 12 weeks of study drug administration.
The mean of the 2 values at each assessment was used in analysis.
|
Baseline and Week 12 (end of Phase A)
|
Change From Baseline in Waist Circumference at Week 12 in Participants With Higher BMI
Ramy czasowe: Baseline and Week 12 (end of Phase A)
|
Waist circumference measured in cm at baseline and after 12 weeks of study drug administration
|
Baseline and Week 12 (end of Phase A)
|
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 in Participants With Higher Body Mass Indices (BMI)
Ramy czasowe: Baseline and Week 12 (end of Phase A)
|
LDL-C was calculated by the method of Friedewald equation at baseline and after 12 weeks of study drug administration.
|
Baseline and Week 12 (end of Phase A)
|
Change From Baseline for High Density Lipoprotein Cholesterol (HDL-C) at Week 12 in Participants With Higher BMI
Ramy czasowe: Baseline and Week 12 (end of Phase A)
|
HDL-C measured at baseline and after 12 weeks of study drug administration.
|
Baseline and Week 12 (end of Phase A)
|
Percent Change From Baseline in Triglycerides (TG) at Week 12 in Participants With Higher Body Mass Indices (BMI)
Ramy czasowe: Baseline and Week 12 (end of Phase A)
|
TG measured at baseline and after 12 weeks of study drug administration
|
Baseline and Week 12 (end of Phase A)
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 0736-003
- 2006_004
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Placebo
-
SamA Pharmaceutical Co., LtdNieznanyOstre zapalenie oskrzeli | Ostra infekcja górnych dróg oddechowychRepublika Korei
-
National Institute on Drug Abuse (NIDA)ZakończonyUżywanie konopi indyjskichStany Zjednoczone
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyZakończonyMężczyźni z cukrzycą typu II (T2DM)Niemcy
-
Heptares Therapeutics LimitedZakończonyFarmakokinetyka | Problemy z bezpieczeństwemZjednoczone Królestwo
-
Soroka University Medical CenterZakończony
-
Regado Biosciences, Inc.ZakończonyZdrowy ochotnikStany Zjednoczone
-
West Penn Allegheny Health SystemZakończonyAstma | Alergiczny nieżyt nosaStany Zjednoczone
-
Longeveron Inc.ZakończonyZespół niedorozwoju lewego sercaStany Zjednoczone
-
ItalfarmacoZakończonyDystrofia mięśniowa BeckeraHolandia, Włochy